CL2019000209A1 - Formulación novedosa administrable por la vía oral. - Google Patents

Formulación novedosa administrable por la vía oral.

Info

Publication number
CL2019000209A1
CL2019000209A1 CL2019000209A CL2019000209A CL2019000209A1 CL 2019000209 A1 CL2019000209 A1 CL 2019000209A1 CL 2019000209 A CL2019000209 A CL 2019000209A CL 2019000209 A CL2019000209 A CL 2019000209A CL 2019000209 A1 CL2019000209 A1 CL 2019000209A1
Authority
CL
Chile
Prior art keywords
orally administrable
administrable formulation
pharmaceutical agent
particles
novel orally
Prior art date
Application number
CL2019000209A
Other languages
English (en)
Inventor
Allen Greenspoon
Original Assignee
Allen Greenspoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen Greenspoon filed Critical Allen Greenspoon
Publication of CL2019000209A1 publication Critical patent/CL2019000209A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

FORMULACIÓN ADMINISTRABLE ORALMENTE CONSISTENTE EN UNA GOMA DE MASCAR QUE COMPRENDE UNA BASE DE GOMA FARMACÉUTICAMENTE ACEPTABLE Y PARTÍCULAS DE UN AGENTE FARMACÉUTICO QUE VARÍAN EN TAMAÑO DESDE APROXIMADAMENTE 50 HASTA APROXIMADAMENTE 2000 µM EN EL QUE LA FORMULACIÓN COMPRENDE APROXIMADAMENTE 0,5-30% EN PESO DE LAS PARTÍCULAS DE AGENTE FARMACÉUTICO. TAMBIÉN SE PROPORCIONA UNA FORMULACIÓN LÍQUIDA QUE COMPRENDE PARTÍCULAS DE UN AGENTE FARMACÉUTICO.
CL2019000209A 2016-07-28 2019-01-25 Formulación novedosa administrable por la vía oral. CL2019000209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/222,019 US9833408B1 (en) 2016-07-28 2016-07-28 Orally administrable formulation

Publications (1)

Publication Number Publication Date
CL2019000209A1 true CL2019000209A1 (es) 2019-09-27

Family

ID=60451833

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000209A CL2019000209A1 (es) 2016-07-28 2019-01-25 Formulación novedosa administrable por la vía oral.

Country Status (13)

Country Link
US (2) US9833408B1 (es)
EP (2) EP3490539B1 (es)
JP (2) JP7050777B2 (es)
AU (2) AU2017301239B2 (es)
BR (2) BR122020007418B1 (es)
CL (1) CL2019000209A1 (es)
CO (1) CO2019001895A2 (es)
CU (1) CU20190005A7 (es)
IL (1) IL264484A (es)
MX (1) MX2019001169A (es)
PE (1) PE20190738A1 (es)
WO (1) WO2018018152A1 (es)
ZA (2) ZA201901116B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11397962B2 (en) 2017-10-09 2022-07-26 American Express Travel Related Services Company, Inc. Loyalty point distributions using a decentralized loyalty ID
US11699166B2 (en) 2017-10-09 2023-07-11 American Express Travel Related Services Company, Inc. Multi-merchant loyalty point partnership
US11449887B2 (en) 2017-10-09 2022-09-20 American Express Travel Related Services Company, Inc. Systems and methods for loyalty point distribution
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3549579A1 (en) * 2018-04-03 2019-10-09 Sanofi Winthrop Industrie Oral gum formulation and fabrication process thereof
CA3096062A1 (en) * 2018-04-03 2019-10-10 Pure Green, Llc Tablet or composition having n-acyl ethanolamine and cannabinoid
US11728995B2 (en) 2018-04-09 2023-08-15 American Express Travel Related Services Company, Inc. Reward point transfers using blockchain
US10783545B2 (en) 2018-04-19 2020-09-22 American Express Travel Related Services Company, Inc. Reward point redemption for cryptocurrency
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US11406593B2 (en) 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
AU2019425173B2 (en) * 2019-01-25 2023-01-05 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
WO2020151790A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Cannabinoid chewing gum with high intensity sweeteners
EP3914226A1 (en) * 2019-01-25 2021-12-01 NordicCan A/S Cannabinoid chewing gum with improved release of cannabinoids
EP4233563A3 (en) * 2019-01-25 2023-11-01 NordicCan A/S Cannabinoid chewing gum with sugar alcohols
US11191720B2 (en) 2019-01-25 2021-12-07 Nordiccan A/S Chewing gum with improved delivery of cannabinoids
US11013685B2 (en) * 2019-01-25 2021-05-25 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
WO2020151793A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Chewing gum with improved delivery of cannabinoids
US11154496B2 (en) * 2019-01-25 2021-10-26 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
US10799450B2 (en) 2019-03-01 2020-10-13 Medcan Pharma A/S Tableted cannabinoid chewing gum with layered structure
US11471405B2 (en) 2019-03-01 2022-10-18 Nordiccan A/S Tableted chewing gum with enhanced delivery of cannabinoids
US10933017B2 (en) 2019-03-01 2021-03-02 Nordiccan A/S Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11253473B2 (en) * 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
US11331309B2 (en) * 2019-06-05 2022-05-17 Cure Pharmaceutical Holding Corp. Methods and compositions for improving sleep
WO2021026557A1 (en) * 2019-08-02 2021-02-11 Advanced Female Technologies Llc Chewing gum compositions containing cannabinoids
WO2021084543A1 (en) * 2019-10-31 2021-05-06 M. Mustix Ltd Treatment of tooth decay using a chewing gum composition comprising cannabinoids
JP2023504756A (ja) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド カンナビノイドを含む口腔用製品
WO2021116825A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
US11058142B1 (en) 2020-10-01 2021-07-13 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same
WO2022072031A1 (en) 2020-10-01 2022-04-07 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing, product, and method of making the same
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243602A1 (en) * 2020-11-16 2023-09-20 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
WO2023064318A1 (en) * 2021-10-11 2023-04-20 Natural Extraction Systems, LLC Biphasic compositions comprising one or both of carbonate and phosphate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816265A (en) * 1986-12-23 1989-03-28 Warner-Lambert Company Sweetener delivery systems containing polyvinyl acetate
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US6132762A (en) * 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
CA2402020C (en) * 2000-03-09 2006-08-29 Gw Pharma Limited Pharmaceutical compositions
US7357943B2 (en) * 2000-12-07 2008-04-15 Nycomed Gmbh Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CN101516333A (zh) * 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
PT2280687T (pt) * 2008-03-26 2019-06-04 Stichting Sanammad Composições de goma de mascar compreendendo canabinóides
KR20110053983A (ko) * 2008-08-29 2011-05-24 썬 파마 어드밴스트 리서치 컴패니 리미티드 미립자
JP5614571B2 (ja) * 2009-12-25 2014-10-29 ダイヤ製薬株式会社 咀嚼用ガム医薬品および咀嚼用ガム医薬品の製造方法
JP2014506894A (ja) * 2011-02-28 2014-03-20 テクノロジーズ・クロロス・インク 口腔吸収用の咀嚼可能なビヒクル
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
CA2904968A1 (en) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US20160199299A1 (en) * 2015-01-09 2016-07-14 Mark B. Uren Cannabis Infused Chewing Composition
CN105124747B (zh) * 2015-07-21 2018-04-10 中国烟草总公司广东省公司 一种烟草提取物微粒和胶基型口香烟及其制备方法
CA3025559C (en) * 2016-05-27 2023-08-01 Medcan Pharma A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
CA3028160C (en) * 2016-07-28 2021-03-30 Allen Greenspoon Orally administrable formulation
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation

Also Published As

Publication number Publication date
CU20190005A7 (es) 2020-03-04
US10456357B2 (en) 2019-10-29
ZA202001037B (en) 2020-07-29
AU2020257071B2 (en) 2021-03-25
EP3490539A1 (en) 2019-06-05
AU2017301239B2 (en) 2020-10-08
AU2017301239A1 (en) 2019-03-14
AU2020257071A1 (en) 2020-11-19
BR112019001572B1 (pt) 2021-11-03
ZA201901116B (en) 2020-10-28
PE20190738A1 (es) 2019-05-23
JP2022088537A (ja) 2022-06-14
JP2019525963A (ja) 2019-09-12
WO2018018152A1 (en) 2018-02-01
EP4353221A2 (en) 2024-04-17
EP3490539B1 (en) 2024-03-13
US9833408B1 (en) 2017-12-05
US20180064645A1 (en) 2018-03-08
EP3490539A4 (en) 2020-08-12
BR112019001572A2 (pt) 2019-05-07
JP7050777B2 (ja) 2022-04-08
BR122020007418B1 (pt) 2021-11-03
CO2019001895A2 (es) 2019-05-31
IL264484A (en) 2019-02-28
MX2019001169A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
MX2021006035A (es) Formulaciones cannabinoides estables.
AR026745A1 (es) Composiciones de eplerenona nanoparticulada
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
DOP2017000293A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
WO2020044119A3 (en) Oral formulations of lavender and cannabinoids
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
PE20120422A1 (es) Formulaciones orales solidas de (r)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil-7,8-dihidro-6h-pirido-[4,3-d]-pirimidin-5-ona
CL2021001621A1 (es) Formulaciones orales de branaplam
MY197663A (en) Pharmaceutical formulation
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
CL2007001713A1 (es) Composicion farmaceutica oral en forma de suspension acuosa que comprende particulas del antihelmintico carbamato de bencimidazol con un 90% de tamano promedio menor que 450 nm y un surfactante polisorbato; metodo para su preparcion; metodo para preparar un medicamento; y uso para controlar infecciones parasitarias en animales.
CO2017000354A2 (es) Desmopresina estabilizada
TR201722102A2 (tr) Levodropropizin İçeren Farmasötik Bir Ürün